{
    "info": {
        "nct_id": "NCT03066648",
        "official_title": "Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
        "inclusion_criteria": "1. Written informed consent must be obtained prior to any screening procedures\n2. Male or female patients ≥ 18 years of age who present with one of the following:\n\n   Arms 1-3:\n   * Relapsed/refractory AML following ≥1 prior therapies who have relapsed or exhibited refractory disease (primary failure) and are deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)\n   * Newly diagnosed AML patients who are suitable for treatment with decitabine (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)\n   * Intermediate or high risk MDS or MDS/MPN including CMML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)\n\n   Arms 4-5:\n   * Refractory / relapsed AML following ≥1 prior therapies (Arms 4a & 5a)\n   * Intermediate or high risk MDS or MDS/MPN including CMML who have failed hypomethylating agent therapy (Arms 4b & 5b) (Note: hypomethylating agent failure is defined as progressive disease on hypomethylating agent therapy or lack of clinically meaningful response as deemed by investigator after at least 4 cycles of hypomethylating agent therapy.)\n\n   Arm 6:\n   * Newly diagnosed AML patients who are suitable for treatment with azacitidine (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) (Arm 6a)\n   * Intermediate or high-risk MDS or MDS/MPN including CMML (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) (Arm 6b)\n3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n4. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions guidelines and be willing to undergo a bone marrow aspirate and/biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.\n5. Arms 1-3: Patients must be fit for standard treatment with decitabine as determined by the investigator and as per local decitabine package insert.\n6. Arm 6: Patients must be fit for standard treatment with azacitidine as determined by the investigator and as per the local azacitidine package insert.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Arms 1-3 or Arm 6: Patients who have received prior hypomethylating agent treatment for AML or MDS.\n2. Patients with active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur should not be excluded.\n3. History of, or current drug-induced interstitial lung disease or pneumonitis grade ≥ 2.\n4. Patients who discontinued prior PD-1 or PD-L1 directed therapy due to a treatment related toxicity should not be included in the PDR001 containing arms of the study. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.\n5. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alphainterferon, kinase inhibitors or other targeted small molecules, and toxinimmunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment.\n6. Systemic chronic corticosteroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Intermediate or high risk MDS or MDS/MPN including CMML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)",
            "criterions": [
                {
                    "exact_snippets": "Intermediate or high risk MDS or MDS/MPN including CMML",
                    "criterion": "myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN) including chronic myelomonocytic leukemia (CMML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "intermediate risk MDS",
                                "high risk MDS",
                                "intermediate risk MDS/MPN",
                                "high risk MDS/MPN",
                                "CMML"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded",
                    "criterion": "suitability and willingness for standard re-induction chemotherapy or hematopoietic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "suitability for standard re-induction chemotherapy or hematopoietic stem cell transplantation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "willingness to receive standard re-induction chemotherapy or hematopoietic stem cell transplantation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory / relapsed AML following ≥1 prior therapies (Arms 4a & 5a)",
            "criterions": [
                {
                    "exact_snippets": "Refractory / relapsed AML",
                    "criterion": "acute myeloid leukemia (AML) status",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "refractory",
                                "relapsed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "following ≥1 prior therapies",
                    "criterion": "number of prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapies"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intermediate or high risk MDS or MDS/MPN including CMML who have failed hypomethylating agent therapy (Arms 4b & 5b) (Note: hypomethylating agent failure is defined as progressive disease on hypomethylating agent therapy or lack of clinically meaningful response as deemed by investigator after at least 4 cycles of hypomethylating agent therapy.)",
            "criterions": [
                {
                    "exact_snippets": "Intermediate or high risk MDS or MDS/MPN including CMML",
                    "criterion": "disease diagnosis and risk category",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "intermediate risk MDS",
                                "high risk MDS",
                                "intermediate risk MDS/MPN",
                                "high risk MDS/MPN",
                                "CMML"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "who have failed hypomethylating agent therapy ... hypomethylating agent failure is defined as progressive disease on hypomethylating agent therapy or lack of clinically meaningful response as deemed by investigator after at least 4 cycles of hypomethylating agent therapy",
                    "criterion": "response to hypomethylating agent therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment failure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "failure definition",
                            "expected_value": [
                                "progressive disease on hypomethylating agent therapy",
                                "lack of clinically meaningful response as deemed by investigator after at least 4 cycles of hypomethylating agent therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Newly diagnosed AML patients who are suitable for treatment with azacitidine (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) (Arm 6a)",
            "criterions": [
                {
                    "exact_snippets": "Newly diagnosed AML patients",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        }
                    ]
                },
                {
                    "exact_snippets": "suitable for treatment with azacitidine",
                    "criterion": "suitability for azacitidine treatment",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded",
                    "criterion": "suitability for standard induction chemotherapy or hematopoietic stem cell transplantation and willingness to receive it",
                    "requirements": [
                        {
                            "requirement_type": "suitability and willingness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Male or female patients ≥ 18 years of age who present with one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Male or female patients",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Written informed consent must be obtained prior to any screening procedures",
            "criterions": [
                {
                    "exact_snippets": "Written informed consent must be obtained",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "obtained",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "form",
                            "expected_value": "written"
                        }
                    ]
                },
                {
                    "exact_snippets": "prior to any screening procedures",
                    "criterion": "timing of informed consent",
                    "requirements": [
                        {
                            "requirement_type": "relative timing",
                            "expected_value": "before screening procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Arms 1-3: Patients must be fit for standard treatment with decitabine as determined by the investigator and as per local decitabine package insert.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be fit for standard treatment with decitabine as determined by the investigator and as per local decitabine package insert",
                    "criterion": "fitness for standard treatment with decitabine",
                    "requirements": [
                        {
                            "requirement_type": "fitness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determined by",
                            "expected_value": "investigator"
                        },
                        {
                            "requirement_type": "according to",
                            "expected_value": "local decitabine package insert"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions guidelines and be willing to undergo a bone marrow aspirate and/biopsy at screening, during and at the end of therapy on this study. Exceptions may be considered after documented discussion with Novartis.",
            "criterions": [
                {
                    "exact_snippets": "Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions guidelines",
                    "criterion": "candidate for serial bone marrow aspirate and/or biopsy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "be willing to undergo a bone marrow aspirate and/biopsy at screening, during and at the end of therapy on this study",
                    "criterion": "willingness to undergo bone marrow aspirate and/or biopsy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "screening",
                                "during therapy",
                                "end of therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Newly diagnosed AML patients who are suitable for treatment with decitabine (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)",
            "criterions": [
                {
                    "exact_snippets": "Newly diagnosed AML patients",
                    "criterion": "acute myeloid leukemia (AML) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "newly diagnosed"
                        },
                        {
                            "requirement_type": "disease type",
                            "expected_value": "acute myeloid leukemia"
                        }
                    ]
                },
                {
                    "exact_snippets": "suitable for treatment with decitabine",
                    "criterion": "suitability for decitabine treatment",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation ... are excluded",
                    "criterion": "suitability for standard induction chemotherapy or hematopoietic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Relapsed/refractory AML following ≥1 prior therapies who have relapsed or exhibited refractory disease (primary failure) and are deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML (patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded)",
            "criterions": [
                {
                    "exact_snippets": "Relapsed/refractory AML following ≥1 prior therapies",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        },
                        {
                            "requirement_type": "prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapies"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "who have relapsed or exhibited refractory disease (primary failure)",
                    "criterion": "disease response to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": [
                                "relapsed",
                                "refractory (primary failure)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "deemed by the investigator not to be candidates for standard therapy, including re-induction with cytarabine or other established chemotherapy regimens for patients with AML",
                    "criterion": "eligibility for standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "candidate for standard therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are suitable for standard re-induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded",
                    "criterion": "suitability and willingness for standard re-induction chemotherapy or hematopoietic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "suitability for standard re-induction chemotherapy or hematopoietic stem cell transplantation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "willingness to receive standard re-induction chemotherapy or hematopoietic stem cell transplantation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intermediate or high-risk MDS or MDS/MPN including CMML (patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded) (Arm 6b)",
            "criterions": [
                {
                    "exact_snippets": "Intermediate or high-risk MDS or MDS/MPN including CMML",
                    "criterion": "myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN) including chronic myelomonocytic leukemia (CMML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "intermediate-risk MDS",
                                "high-risk MDS",
                                "intermediate-risk MDS/MPN",
                                "high-risk MDS/MPN",
                                "CMML"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are suitable for standard induction chemotherapy or hematopoietic stem cell transplantation and willing to receive it are excluded",
                    "criterion": "suitability and willingness for standard induction chemotherapy or hematopoietic stem cell transplantation",
                    "requirements": [
                        {
                            "requirement_type": "suitability for standard induction chemotherapy or hematopoietic stem cell transplantation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "willingness to receive standard induction chemotherapy or hematopoietic stem cell transplantation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Arm 6: Patients must be fit for standard treatment with azacitidine as determined by the investigator and as per the local azacitidine package insert.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be fit for standard treatment with azacitidine as determined by the investigator and as per the local azacitidine package insert",
                    "criterion": "fitness for standard treatment with azacitidine",
                    "requirements": [
                        {
                            "requirement_type": "fitness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determined by",
                            "expected_value": "investigator"
                        },
                        {
                            "requirement_type": "per local azacitidine package insert",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "5. Systemic antineoplastic therapy (including cytotoxic chemotherapy, alphainterferon, kinase inhibitors or other targeted small molecules, and toxinimmunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Systemic antineoplastic therapy (including cytotoxic chemotherapy, alphainterferon, kinase inhibitors or other targeted small molecules, and toxinimmunoconjugates) or any experimental therapy within 14 days or 5 half-lives, whichever is shorter, before the first dose of study treatment.",
                    "criterion": "systemic antineoplastic therapy or experimental therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Patients who discontinued prior PD-1 or PD-L1 directed therapy due to a treatment related toxicity should not be included in the PDR001 containing arms of the study. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patients who discontinued prior PD-1 or PD-L1 directed therapy due to a treatment related toxicity should not be included in the PDR001 containing arms of the study.",
                    "criterion": "discontinuation of prior PD-1 or PD-L1 therapy due to treatment related toxicity",
                    "requirements": [
                        {
                            "requirement_type": "history of discontinuation due to toxicity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.",
                    "criterion": "adequate treatment for skin rash or with replacement therapy for endocrinopathies after anti-PD-1/PD-L1 exposure",
                    "requirements": [
                        {
                            "requirement_type": "adequate treatment for skin rash or endocrinopathies",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. History of, or current drug-induced interstitial lung disease or pneumonitis grade ≥ 2.",
            "criterions": [
                {
                    "exact_snippets": "History of, or current drug-induced interstitial lung disease",
                    "criterion": "drug-induced interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history or current presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pneumonitis grade ≥ 2",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Arms 1-3 or Arm 6: Patients who have received prior hypomethylating agent treatment for AML or MDS.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received prior hypomethylating agent treatment for AML or MDS",
                    "criterion": "prior hypomethylating agent treatment for AML or MDS",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Systemic chronic corticosteroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.",
            "criterions": [
                {
                    "exact_snippets": "Systemic chronic corticosteroid therapy (>10 mg/day prednisone or equivalent) ... within 7 days of first dose of study treatment",
                    "criterion": "systemic chronic corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any immunosuppressive therapy within 7 days of first dose of study treatment",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before first dose of study treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Topical, inhaled, nasal and ophthalmic steroids are allowed",
                    "criterion": "topical, inhaled, nasal and ophthalmic steroids",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Patients with active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur should not be excluded.",
            "criterions": [
                {
                    "exact_snippets": "Patients with active, known or suspected autoimmune disease.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur should not be excluded.",
                    "criterion": "vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "type I diabetes ... should not be excluded.",
                    "criterion": "type I diabetes",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "residual hypothyroidism only requiring hormone replacement ... should not be excluded.",
                    "criterion": "residual hypothyroidism (only requiring hormone replacement)",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "psoriasis not requiring systemic treatment ... should not be excluded.",
                    "criterion": "psoriasis (not requiring systemic treatment)",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "conditions not expected to recur should not be excluded.",
                    "criterion": "autoimmune conditions not expected to recur",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Other protocol-defined inclusion/exclusion criteria may apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined inclusion/exclusion criteria may apply.",
                    "criterion": "protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Arm 6:",
            "criterions": []
        },
        {
            "line": "Arms 4-5:",
            "criterions": []
        },
        {
            "line": "Arms 1-3:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}